John Reed, Sanofi R&D chief (Jeff Rumans)
May 13, 2020 10:11 AM EDT
R&D

Sanofi flash­es more PhI­II da­ta on new mul­ti­ple myelo­ma drug, set­ting up bat­tle with Darza­lex

Jason Mast

Editor

Two months af­ter nab­bing their first ap­proved can­cer drug in a decade, Sanofi an­nounced new late-stage da­ta bur­nish­ing the drug’s ef­fi­ca­cy in an­oth­er com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times